RBC Capital Reiterates Outperform on Mirum Pharmaceuticals, Maintains $155 Price Target

Benzinga · 2d ago
RBC Capital analyst Luca Issi reiterates Mirum Pharmaceuticals (NASDAQ:MIRM) with a Outperform and maintains $155 price target.